title: Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review.
abstract: This paper reviews the results of an acute phase trial and a five-year follow-up study of fluoxetine in adolescents with major depression and a substance use disorder (SUD). This study included a 12-week open label acute phase study of 13 comorbid adolescents, followed by comprehensive assessments conducted 1, 3, and 5 years after entry into an acute phase fluoxetine trial. The results of the acute phase study and of the 1, 3, and 5-year follow-up assessments have already been published in four papers. The current paper was designed to cover the results of the study across the entire 5-year time spectrum of the study, and to summarize the clinical results across that entire time period. The data from this pilot study suggest that the long-term (5-year) clinical course for the Alcohol Dependence, Cannabis Dependence, and academic functioning of comorbid adolescents following acute phase treatment with SSRIs is generally good. However, the long-term clinical course for the Major Depression of that comorbid adolescent population is surprisingly poor.
authors.affiliation: Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, PAARC Suite, Pittsburgh, PA 15213, USA. jcornel@pitt.edu
authors.forename: Jack R
authors.initials: JR
authors.lastname: Cornelius
authors.forename: Duncan B
authors.initials: DB
authors.lastname: Clark
authors.forename: Oscar G
authors.initials: OG
authors.lastname: Bukstein
authors.forename: Boris
authors.initials: B
authors.lastname: Birmaher
authors.forename: Ihsan M
authors.initials: IM
authors.lastname: Salloum
authors.forename: Sandra A
authors.initials: SA
authors.lastname: Brown
mesh_terms: D000293:Adolescent; D000428:Alcohol Drinking / Q000523:psychology; D000437:Alcoholism / Q000523:psychology; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000379:methods; D003865:Major Depressive Disorder / Q000150:complications / Q000188:drug therapy*; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D002189:Marijuana Abuse / Q000523:psychology; D010865:Pilot Projects; D011613:Psychotherapy / Q000379:methods; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D019966:Substance-Related Disorders / Q000150:complications*; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors